Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Accumulated Expenses of $2.2 million for Q1 2026, down 83.15% year-over-year from $13.3 million in Q1 2025, and down 51.02% quarter-over-quarter from $4.6 million in Q4 2025.
Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Accumulated Expenses for 7 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 83.15% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 83.15% YoY), while the FY2025 annual figure was $4.6 million, down 60.72% from the prior year.
- Accumulated Expenses declined to $2.2 million in Q1 2026 per JANX's latest filing, from $4.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $16.0 million in Q2 2025 and bottomed at $1.4 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $5.8 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 823.47% — and 2026, when it sank 83.15%.
- Janux Therapeutics' Accumulated Expenses stood at $8.2 million in 2022, then sank by 59.62% to $3.3 million in 2023, then soared by 253.74% to $11.7 million in 2024, then sank by 60.72% to $4.6 million in 2025, then plunged by 51.02% to $2.2 million in 2026.
- Business Quant data shows JANX's Accumulated Expenses at $2.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.51 Mn |
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Jun 30, 2025 | 16.03 Mn |
| Mar 31, 2025 | 13.34 Mn |
| Dec 31, 2024 | 11.68 Mn |
| Sep 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | 8.57 Mn |
| Mar 31, 2024 | 5.81 Mn |
| Dec 31, 2023 | 3.30 Mn |
| Sep 30, 2023 | 6.83 Mn |
| Jun 30, 2023 | 9.22 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 8.18 Mn |
| Sep 30, 2022 | 7.24 Mn |
| Jun 30, 2022 | 4.04 Mn |
| Mar 31, 2022 | 5.07 Mn |
| Dec 31, 2021 | 3.78 Mn |
| Sep 30, 2021 | 784,000.00 |